| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CSO &EVP, Head Of Research
2 companies
Fitzgerald Kevin Joseph is a CSO &EVP, Head Of Research at ALNYLAM PHARMACEUTICALS, INC. with holdings across 2 companies. Recent SEC Form 4 filings include 0 buys and 124 sells.
Estimated insider holdings value: $6.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 3,800 | $367.37 | $1,395,992.00 | -0.6% | -12.9% | - | |
| Nov 17, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sale+OE | 12,128 | $452.18 | $5,483,989.61 | -4.5% | -27.8% | - | |
| Oct 2, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 2,441 | $452.05 | $1,103,451.46 | -0.8% | -13.7% | - | |
| Aug 18, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 1,396 | $453.27 | $632,758.71 | -0.7% | +0.8% | - | |
| Mar 4, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 2,755 | $242.94 | $669,304.07 | -1.3% | +26.0% | +34.7% | |
| Feb 28, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 496 | $241.69 | $119,877.91 | -0.5% | +18.7% | +34.9% | |
| Feb 18, 2025 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 2,103 | $252.71 | $531,447.79 | -0.9% | +16.7% | +33.1% | |
| Nov 27, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 3,000 | $251.65 | $754,946.54 | -2.3% | -3.4% | +77.8% | |
| Aug 12, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sale+OE | 22,025 | $270.99 | $5,968,515.60 | -16.0% | +3.6% | +59.1% | |
| Jun 25, 2024 | ALNY Alnylam Pharmaceuticals, Inc. | CSO &EVP, Head Of Research | Sell | 1,198 | $230.99 | $276,730.75 | -0.7% | +13.2% | +34.1% |